Tesamorelin (10 mg Vial) – Dosage Protocol
Contents
- Quickstart Highlights
- Dosing & Reconstitution Guide
- Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
- Reconstitution Steps
- Supplies Needed
- Protocol Overview
- Dosing Protocol
- Storage Instructions
- Important Notes
- How This Works
- Potential Benefits & Side Effects
- Lifestyle Factors
- Injection Technique
- Recommended Source
- Important Note
- References
Quickstart Highlights
Tesamorelin is a synthetic 44-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH). It works by stimulating the body’s natural production of growth hormone, leading to increased IGF-1 levels and enhanced fat metabolism.
It is FDA-approved for reducing visceral fat in individuals with HIV-associated lipodystrophy and has also been studied for metabolic health, fat loss, and aging-related applications.
This protocol outlines a structured once-daily subcutaneous dosage method using a standard reconstitution approach for precise measurement.
- Reconstitution: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration
- Standard Daily Dosage: 2 mg (2000 mcg) once daily
- Measurement Guide: 1 unit ≈ 33.3 mcg (U-100 insulin syringe)
- Storage:
- Lyophilized: 2–8°C
- Reconstituted: 2–8°C (use within 7 days)
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mg / mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 1 mg / 1000 mcg | 30 units (0.30 mL) |
| Weeks 2–12+ | 2 mg / 2000 mcg | 60 units (0.60 mL) |
Frequency: Inject once daily via subcutaneous injection, preferably in the evening to align with natural growth hormone release cycles.
A short 1-week titration phase at 1 mg is often used to improve tolerance before increasing to the full 2 mg dosage
Reconstitution Steps
- Using a sterile syringe, draw 3.0 mL bacteriostatic water.
- Slowly inject the liquid down the inside wall of the vial to minimize foaming.
- Gently swirl or roll the vial until the powder is fully dissolved. Avoid shaking, as peptides are delicate.
- Clearly label the vial and place it in refrigeration (2–8°C), away from direct light exposure.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Estimated requirements based on an 8–16 week protocol at 2 mg daily dosage:
Tesamorelin 10 mg Vials
- 8 weeks: ~11 vials
- 12 weeks: ~17 vials
- 16 weeks: ~22 vials
Insulin Syringes (U-100)
- 1 per day
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
Bacteriostatic Water (10 mL Bottles)
- ~3.0 mL per vial
- 8 weeks: ~4 bottles
- 12 weeks: ~6 bottles
- 16 weeks: ~7 bottles
Alcohol Swabs
- 2 per day (vial + injection site)
- 8 weeks: ~112 swabs
- 12 weeks: ~168 swabs
- 16 weeks: ~224 swabs
Protocol Overview
A simplified overview of the daily regimen:
- Goal: Reduce visceral fat and improve metabolic health
- Schedule: Daily injections for 12–26 weeks
- Dosage: 2 mg daily after initial titration
- Reconstitution: 3.0 mL per vial
- Storage: Refrigerate; use reconstituted solution within 7 days
Dosing Protocol
A structured dosing approach based on clinical use:
- Week 1: 1 mg (1000 mcg) daily (titration phase)
- Weeks 2+: 2 mg (2000 mcg) daily (standard dosage)
- Frequency: Once daily (subcutaneous)
- Timing: Preferably evening administration
- Cycle Length:
- Standard: 12–26 weeks
- Extended: Up to 52 weeks with monitoring
- Site Rotation: Rotate injection areas regularly
Storage Instructions
Proper storage is essential to maintain stability and effectiveness:
- Lyophilized (unmixed): Store at −20°C for long-term preservation
- Reconstituted: Keep refrigerated at 2–8°C
- Shelf Life: Approximately 30 days after mixing
- Avoid repeated freeze–thaw cycles
- Allow vial to reach room temperature before opening to reduce moisture buildup
Important Notes
- Use a new sterile insulin syringe (27–30G) for each injection
- Dispose of all sharps safely after use
- Rotate injection sites to minimize irritation or tissue buildup
- Inject slowly and wait briefly before removing the needle
- Common temporary effects may include nausea, flushing, or mild headache
- Keeping a simple log of dose and injection site can help maintain consistency
How This Works
Tesamorelin mimics natural GHRH and binds to receptors in the pituitary gland, triggering the release of growth hormone. This leads to increased IGF-1 production, which promotes fat breakdown (lipolysis), muscle preservation, and metabolic improvements.
Clinical research has shown significant reductions in visceral fat and improvements in lipid profiles. It is also being explored for applications in liver fat reduction and cognitive support.
Potential Benefits & Considerations
Potential Benefits
- Reduction in visceral adipose tissue
- Improved metabolic and lipid profiles
- Support for fat loss and body composition
- Possible cognitive and anti-aging benefits
Common Side Effects
- Injection site irritation (redness, itching)
- Mild swelling or joint discomfort
- Temporary fluid retention
Contraindications
- Active malignancy
- Pregnancy
- Hypersensitivity to Tesamorelin
Lifestyle Factors
For optimal outcomes, consider combining with supportive habits:
- Maintain consistent sleep (7–9 hours per night)
- Engage in regular physical activity
- Practice stress management (meditation, breathing exercises)
- Ensure proper nutrition (protein, omega-3s, micronutrients)
- Limit alcohol and excessive stimulant intake
Injection Technique
- Wash hands and prepare a clean surface
- Clean vial stopper with alcohol swab
- Draw correct dosage into syringe and remove air bubbles
- Clean injection site and allow to dry
- Pinch skin and inject at a 90° angle
- Inject slowly and steadily
- Remove needle and apply gentle pressure if needed
- Dispose of syringe safely (do not reuse)
- Rotate injection sites regularly
Recommended Source
We recommend Fit Aminos for high-purity research peptide products.
Why Fit Aminos?
- High-purity, lab-tested peptide batches with quality verification.
- Consistent handling and preparation processes designed to support reliable research protocols.
- Transparent sourcing and dependable fulfillment for research-grade compounds.
Important Note
This content is intended for educational and research purposes only and does not constitute medical advice, diagnosis, or treatment. TESAMORELIN (10mg) remains an investigational peptide with limited human clinical data. For research use only. Not for human consumption.
References
Tesamorelin – LiverTox: Clinical and Research Information on Drug-Induced Liver Injury — National Institutes of Health, NIDDK (2018)
Tesamorelin (Subcutaneous route) – Drug Information — Mayo Clinic / IBM Merative (2025)
Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials
— J. Clin. Endocrinol. Metab. (2010)
Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: A randomized, placebo-controlled trial — PLoS ONE (2017)
Journal of Higher Nervous Activity (Russia) — Early human study introducing Semax’s nootropic properties and mechanism of action